Overview

Spironolactone for the Treatment of Melasma

Status:
Withdrawn

Trial end date:
2021-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to prospectively gather data on the efficacy and tolerability of spironolactone to treat refractory melasma and to compare treatment response of randomized 50 mg, 100mg, and 200mg per day dosing.

Phase:

Phase 1

Details

Lead Sponsor:

Medical University of South Carolina

Treatments:

Spironolactone